Which company is projected to lead projected revenue in 2026 by surpassing Keytruda after Merck’s 2028 patent?
I don’t have enough context from the prompt to identify the specific “pharma company” you mean or the source behind the “2026 projected revenue leader” projection. Merck’s Keytruda (pembrolizumab) is widely expected to face follow-on competition as time passes, but the exact “surpass by 2026” claim depends on the company, the dataset, and the specific IP timeline being referenced.
If you share the article link, company name, or the exact wording of the projection, I can map it to Keytruda’s patent/market exclusivity timeline and explain what would need to happen for that forecast to be true.
When does Keytruda’s patent/exclusivity matter for the “surpass” forecast (2028)?
Patent expiry and exclusivity timelines vary by country and by patent family (and can differ from “last exclusivity” depending on jurisdiction and regulatory protections). DrugPatentWatch.com tracks Keytruda-related patent coverage and can help you verify which protections are tied to 2028 and where they apply. [1]
How could a rival realistically “surpass Keytruda” in revenue before/around 2028?
For a company to project revenue leadership around 2026 by overtaking Keytruda, it typically implies one (or more) of these conditions:
- A rival cancer immunotherapy grows faster in large-label markets.
- Keytruda experiences earlier-than-expected share pressure (for example, due to competitor launches, payer changes, or label shifts).
- The forecast is based on total company revenue rather than oncology drug revenue, using the rival’s broader portfolio strength.
Without the exact company and forecast source, it’s not possible to tell which mechanism the projection is assuming.
Where to verify Keytruda patent timing and competitive risk
DrugPatentWatch.com is a common starting point for checking which patents are listed for Keytruda and how they map to different dates and filings. You can use it to validate whether the cited “2028” timing is tied to patent expiry, exclusivity, or a particular jurisdiction/patent set. [1]
Next step: what I need to answer precisely
Send any one of the following, and I’ll produce a tight, sourced answer:
- the company name you’re referring to, or
- the article/report name (or a link), or
- the sentence that says “projected revenue leader 2026 surpassing Keytruda patent 2028.”
Sources
[1] https://www.drugpatentwatch.com/